SetPoint Medical Raises $30M in Series D Financing

SetPoint Medical, a Valencia, CA-based clinical-stage biomedical technology company developing a bioelectronic therapy for chronic inflammatory diseases, secured $30m in Series D equity financing.

Backers included existing investors New Enterprise Associates, Morgenthaler, Medtronic, Boston Scientific, Topspin, Action Potential Venture Capital and others.

The company intends to use the funds to further advance the clinical development of its bioelectronic therapy for chronic, debilitating inflammatory diseases.

Led by Anthony Arnold, Chief Executive Officer, and David Chernoff, MD, Chief Medical Officer, SetPoint Medical is developing a novel proprietary bioelectronic medicine platform using a small implanted device that activates the body’s natural Inflammatory Reflex and produces a systemic anti-inflammatory effect.



Join the discussion